Literature DB >> 16138114

Retinal artery macroaneurysms: clinical and fluorescein angiographic features in 34 patients.

R A Moosavi1, K C S Fong, A Chopdar.   

Abstract

AIM: To describe the clinical and fluorescein angiographic features of patients with macroaneurysms (MAs) attending an ophthalmology department over 8 years.
METHODS: All the patients between 1997 and 2004 with a diagnosis of retinal artery MA were identified from hospital records. Photographs and fluorescein angiograms were examined, and the MAs classified according to their clinical (haemorrhagic or exudative) features, and angiographic (saccular or fusiform) features. Baseline data of the patients were taken including visual acuity and associated ocular and medical conditions.
RESULTS: A total of 38 MAs were identified in 34 patients. The age at presentation ranged from 36 to 93 years, with a mean of 73.7 years. Of them, 24/34 (70%) were female patients, and 10/34 (30%) were male patients. There was a history of hypertension in 9/14 patients (64.3%). Of 38 MAs, 32 were identifiable as either saccular or fusiform. Of these, 22/32 (68.75%) were saccular, the rest fusiform. In all, 72.7% of the saccular MAs showed haemorrhage as the predominant feature. Of the 10 fusiform MAs, 90% showed haemorrhage as the predominant feature.
CONCLUSION: Retinal artery macroaneurysm is a rare condition that may mimic a variety of other conditions. Most MAs do not require treatment. We suggest guidelines for diagnosis and propose a treatment algorithm for this condition.

Entities:  

Mesh:

Year:  2005        PMID: 16138114     DOI: 10.1038/sj.eye.6702068

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  27 in total

1.  Development of a second retinal artery macroaneurysm within a few months.

Authors:  Fariba Ghassemi; Ali Reza Majidi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-22       Impact factor: 3.117

2.  Intravitreal ranibizumab therapy for retinal arterial macroaneurysm.

Authors:  Muhammet Kazim Erol; Berna Dogan; Deniz Turgut Coban; Devrim Toslak; Ayse Cengiz; Deniz Ozel
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Treatment of intravitreal bevacizumab combined with focal laser photocoagulation in the case of macular telangiectasia type 2 with retinal arterial macroaneurysm.

Authors:  Gökhan Demir; Özgür Artunay; Mehmet Emin Sucu; Ali Demircan; Dilek Yaşa; Cengiz Alagöz; Mevlüt Celal Öcal
Journal:  Lasers Med Sci       Date:  2018-05-26       Impact factor: 3.161

4.  Laser therapy versus observation for symptomatic retinal artery macroaneurysms.

Authors:  Jacob C Meyer; Baseer U Ahmad; Kevin J Blinder; Gaurav K Shah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-13       Impact factor: 3.117

Review 5.  Ruptured retinal arterial macroaneurysm: diagnosis and management.

Authors:  Ashley M Speilburg; Stephanie A Klemencic
Journal:  J Optom       Date:  2013-09-26

6.  Angiographic features and disease outcomes of symptomatic retinal arterial macroaneurysms.

Authors:  Emily L Hughes; Ian J Dooley; Kevin P Kennelly; Fergus Doyle; W F Siah; P Connell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-25       Impact factor: 3.117

7.  Vascular networks in retinal arterial macroaneurysms.

Authors:  Maria-Andreea Gamulescu; Horst Helbig
Journal:  Int Ophthalmol       Date:  2007-12-13       Impact factor: 2.031

8.  Retinal Arterial Macroaneurysms: Updating your Memory on RAM Management.

Authors:  Brian Evan Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2019-04-16

9.  Influence of bevacizumab therapy and intraretinal hemorrhage in long-term outcomes of hemorrhagic retinal arterial macroaneurysm.

Authors:  Jae Hui Kim; Jong Woo Kim; Chul Gu Kim; Young Ju Lew; Han Joo Cho
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

10.  Periretinal Hemorrhage Due to Retinal Arterial Macroaneurysm: The Role of ICG Angiography in Solving a Diagnostic Dilemma.

Authors:  Siamak Moradian; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.